30Jun
Healthcare M&A prospers, despite fall in deal activity
The megadeals of 2019 may be off the table for now, but deal activity across healthcare and pharmaceuticals has proven resilient through the COVID-19 crisis - Although pharma, medical and biotech (PMB) M&A deal value for Q1 2020 came in at US$39.3 billion, 78% below the year before, this was primarily due to the outsized US$87.8 billion deal between Bristol-Myers Squibb and Celgene in early 2019....
By:
White & Case LLP
Related
The U.S. Department of the Treasury late yesterday released a draft set of regulations that would es...
Read More >
On December 12, 2019, the U.S. Department of Labor (“DOL”) finalized a new rule that lets employer...
Read More >
Parliament will have a busy few months ahead. However, to the extent parliamentary time allows, Ther...
Read More >
We’re delighted to report that we secured two summary judgments in two separate alleged discriminat...
Read More >
Are you familiar with PAGA? Do you have a PAGA claim for unpaid wages filed against you right now? I...
Read More >
The National Labor Relations Board has issued its “Ethics Recusal Report,” which announces several...
Read More >